According to Renub Research latest report, "Netherlands Diabetes Market, Size, Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis” the Netherland Diabetes Market will expand at a CAGR of 4.27% from 2023 to 2028. More than a million people in the Netherlands have type 2 diabetes. Diabetes is a chronic disorder, and all varieties of diabetes are likely to become more familiar with time. Furthermore, a key risk factor for diabetes in the Netherlands is the rising obesity incidence and aging population. The high expense of treating diabetes and the unfavourable side effects of several diabetic care devices, however, limit market expansion. Netherlands Diabetes Market was US$ 2.62 Billion in 2022, according to Renub Research.
An Increasing Aging Population will create Type-2 Prevalence in the Netherlands
Having type 2 diabetes poses a serious threat to the public's health and is associated with high rates of morbidity, death, and financial burden. Overweight or obese individuals make up a significant share of type 2 diabetes patients. For many folks, losing weight and keeping it off is very crucial. Type 2 diabetes has been shown to affect the Dutch population over the age of 18. Type 2 diabetes is not becoming more prevalent among kids and teenagers. Patients with type-2 diabetes frequently have severe side effects, including blindness, renal failure, and cardiovascular disease.
However, the aging population of Dutch people is increasing; increasing risk of obesity causes a Type-2 diabetes problem in Dutch people. Type-2 diabetes patients utilize medical specialists and pharmaceutical care. Consequently, the most significant burden in spending is due to hospitalizations, followed by outpatient specialist care and medication.
Government Initiatives
The National Action Program Diabetes (NAD) implementation in the Netherlands over the past decade has helped manage diabetes. It aims to inaugurate the Care Standard (CS) for diabetes using a particular implementation plan and to pilot it in several regions. However, the government has taken numerous initiatives for diabetes care in the Netherlands. The Dutch Health Care Authority has essential liability for making sure that the health insurance, health care purchasing, and care delivery markets all function appropriately and consists of three 'compartments'; the first compartment comprises a compulsory social health insurance scheme for long-term care, which the Exceptional Medical Expenses Act regulates; the second compartment consists of a social health insurance scheme for basic health insurance, which the Zvw handles. The third compartment consists of complementary voluntary health insurance. Health insurers determine coverage and premium; all health insurers offer a variety of policies against different tips.
Insulin Pen Segment captured the Highest Market Share
The increase in overweight and obesity, unhealthy diet, the high base of an aging population, and physical inactivity have significantly driven the demand for insulin pens in the Netherlands. The rise is due to the availability of reimbursement of insulin pens and an increase in the diabetic population. The devices have various benefits, such as easy use, especially for patients with vision problems, the fastest of providing a small dose of insulin, and discretion of service.
In addition, the low cost of an insulin pen makes it more accessible to people of all ages. One of the fastest-growing disorders with a high disease burden and reduction in quality of life is diabetes mellitus. In Dec 2022, the FDA approved a once-weekly Wegovy injection to treat obesity in teens aged 12.
In addition, CGM, SMBG, and Insulin Pumps also have massive demand in the Netherlands due to the growing aging population, increasing prevalence of diabetic patients, rising awareness regarding the benefits of the insulin pump, increasing per capita disposable income, and progressive diabetes infrastructure. As a result, numerous initiatives to enhance the effectiveness and quality of diabetes care in the Netherlands have already been taken in recent years.
Competitive Landscape
Netherland Diabetes Companies include B. Braun Melsungen AG, Sanofi, Eli Lilly and Company, Becton Dickenson (BD), Novo Nordisk A/S, Ypsomed AG, Biocon, Medtronic, Insulet Corporation, Abbott Laboratories, Terumo Corporation, and Dexcom Inc.
In May 2021, Medtronic secured European approvals for its Guardian 4 sensor. The Guardian 4 sensor can be either utilized as a standalone continuous glucose monitor or combined into Medtronic's insulin pumps and pens to add real-time glucose monitoring alongside insulin tracking.
Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=netherlands-diabetes-market-p.php
Market Summary
By Devices: - The Report covers the Netherlands Diabetes Market by devices from 4 viewpoints.
- Self Monitoring Blood Glucose Devices (SMBG) (Test Strips Market, Lancet Market, Meter Market and Forecast, Blood Glucose (SMBG) Users and Blood Glucose Devices Reimbursement)
- Continuous Glucose Monitoring Devices (CGM) (Glucose Sensor Market, CGM Transmitter Market, CGM User, and Reimbursement Policies of CGM devices in Israel)
- Insulin Pump (Insulin Pump Market, Insulin Pump User, and Reimbursement Policies Insulin Pump)
- Insulin Pen – (User, Types – Disposable, Reusable and Smart Insulin Pen, Insulin Pen Needle Market, Reimbursement Policies
Browse Related Report:
Germany Diabetes Market: https://www.renub.com/germany-diabetes-market-p.php
Australia Diabetes Market: https://www.renub.com/australia-diabetes-market-p.php
Switzerland Diabetes Market: https://www.renub.com/switzerland-diabetes-market-p.php
Sweden Diabetes Market: https://www.renub.com/sweden-diabetes-market-p.php
Israel Diabetes Market: https://www.renub.com/israel-diabetes-market-p.php
About the Company:
Renub Research is a Market Research and Information Analysis company with more than 14 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000 syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.
Contact Us:
Renub Research
Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)
Email: [email protected]
LinkedIn: https://in.linkedin.com/company/renub-research
Web: www.renub.com
Comments